CompletedPhase 4

Tolerability of Grazax in Patients With Hayfever in Real Life Settings

France628 participantsStarted 2007-11

Plain-language summary

The purpose of this study is to assess the safety profile of specific immunotherapy with Grazax for three consecutive grass pollen seasons.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * History of grass pollen allergy * Positive skin prick-test and/or positive specific IgE to grass Exclusion Criteria: * Severe, unstable or uncontrolled asthma (FEV1\<70% of predicted value)

What they're measuring

Adverse Events related to Grazax

Timeframe: From November 2007 to October 2010 (3 years)

Trial details

NCT IDNCT01433510

SponsorALK-Abelló A/S

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-10

View on ClinicalTrials.gov More Allergic Rhinoconjunctivitis trials